160 research outputs found
Target mutation-driven drug discovery
In the era of precision medicine, genetics is becoming a key factor for the choice of therapies. For decades, it has been intuitively thought that variability in drug response relies, at least partly, on gene variants that may affect the pharmacokinetics and pharmacodynamics of drugs. The most considerable evidences regard polymorphisms in genes encoding enzymes and carriers involved in the ADME processes. Nowadays, more attention should be paid to genetic variations in drug targets, especially in cancer and rare diseases
Histones differentially modulate the anticoagulant and profibrinolytic activities of heparin, heparin derivatives and dabigatran.
The antithrombin activity of unfractionated heparin (UFH) is offset by extracellular histones, which, along with DNA,
represent a novel mediator of thrombosis and a structural component of thrombi. Here, we systematically evaluated the
effect of histones, DNA, and histone-DNA complexes on the anticoagulant and profibrinolytic activities of UFH, its derivatives
enoxaparin and fondaparinux, and the direct thrombin inhibitor dabigatran. Thrombin generation was assessed by
calibrated automated thrombinography, inhibition of factor Xa and thrombin by synthetic substrates, tissue plasminogen
activator–mediated clot lysis by turbidimetry, and thrombinactivatable fibrinolysis inhibitor (TAFI) activation by a functional
assay. Histones alone delayed coagulation and slightly stimulated fibrinolysis. The anticoagulant activity of UFH and
enoxaparin was markedly inhibited by histones, whereas that of fondaparinux was enhanced. Histones neutralized both the
anti-Xa and anti-IIa activities of UFH and preferentially blocked the anti-IIa activity of enoxaparin. The anti-Xa activity
of fondaparinux was not influenced by histones when analyzed by chromogenic substrates, but was potentiated in a
plasma prothrombinase assay. Histones inhibited the profibrinolytic activity of UFH and enoxaparin and enhanced that of
fondaparinux by acting on the modulation of TAFI activation by anticoagulants. Histone H1 was mainly responsible for
these effects. Histone-DNA complexes, as well as intact neutrophil extracellular traps, impaired the activities of UFH,
enoxaparin, and fondaparinux. Dabigatran was not noticeably affected by histones and/or DNA, whatever the assay performed.
In conclusion, histones and DNA present in the forming clot may variably influence the antithrombotic activities
of anticoagulants, suggesting a potential therapeutic advantage of dabigatran and fondaparinux over heparin
Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity
Although the sodium channel blocker, mexiletine, is the first choice drug in myotonia, some myotonic patients remain unsatisfied due to contraindications, lack of tolerability, or incomplete response. More therapeutic options are thus needed for myotonic patients, which require clinical trials based on solid preclinical data. In previous structure-activity relationship studies, we identified two newly-synthesized derivatives of tocainide, To040 and To042, with greatly enhanced potency and use-dependent behavior in inhibiting sodium currents in frog skeletal muscle fibers. The current study was performed to verify their potential as antimyotonic agents. Patch-clamp experiments show that both compounds, especially To042, are greatly more potent and use-dependent blockers of human skeletal muscle hNav1.4 channels compared to tocainide and mexiletine. Reduced effects on F1586C hNav1.4 mutant suggest that the compounds bind to the local anesthetic receptor, but that the increased hindrance and lipophilia of the N-substituent may further strengthen drug-receptor interaction and use-dependence. Compared to mexiletine, To042 was 120 times more potent to block hNav1.4 channels in a myotonia-like cellular condition and 100 times more potent to improve muscle stiffness in vivo in a previously-validated rat model of myotonia. To explore toxicological profile, To042 was tested on hERG potassium currents, motor coordination using rotarod, and C2C12 cell line for cytotoxicity. All these experiments suggest a satisfactory therapeutic index for To042. This study shows that, owing to a huge use-dependent block of sodium channels, To042 is a promising candidate drug for myotonia and possibly other membrane excitability disorders, warranting further preclinical and human studies
- …